
Steve Strazza Had Bought 10x Genomics. CRISPR Therapeutics Still Had to Clear Its Range.
When a viewer asked about CRISPR Therapeutics on June 29, 2023, Strazza brought up another genomics stock. Its trading range had narrowed for months, and $54 gave him a price to work against.